Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NAD busts Shoreline

This article was originally published in The Tan Sheet

Executive Summary

Latavi breast enhancement product marketer Shoreline Enterprises has "failed to provide a substantive written response" to defend claims for its "all-natural" supplement, National Advertising Division says in recent Case Reports, referring issue to FTC. Wellquest International challenged print, radio ads for Latavi, which claims to "enlarge and tone your breasts and increase the size of your breasts at least two cup sizes, guaranteed." In response, Shoreline claimed its product substantiation is proprietary and would not submit written documentation to CBBB division. Wellquest recently initiated a similar case against CP Nutritionals (1"The Tan Sheet" Sept. 23, 2002, p. 18)...

You may also be interested in...



NAD keeps abreast of misleading claims

Testimonial evidence offered in support of CP Nutritionals' claims for Full & Firm breast enhancement capsules is "inadequate and insufficient to substantiate the underlying claims of product performance and safety," Council of Better Business Bureaus National Advertising Division concludes in September Case Reports. Wellquest International challenged claims that Full & Firm capsules, which contain "eight natural herbs," promote "dramatic breast growth so quick, most women actually 'feel' their breasts growing" and "the longer you take them, the more they'll expand your breast tissue." Although CP Nutritionals defended its ads, firm has halted all promotions and "been put into receivership by the Arizona Superior Court of Maricopa County by action of the Attorney General of Arizona," NAD notes...

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.

MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In

The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094620

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel